Study of Olutasidenib and Temozolomide in HGG

NCT06161974 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

High Grade Glioma
Astrocytoma
Astrocytoma, Grade III
Astrocytoma, Grade IV
Diffuse Intrinsic Pontine Glioma
WHO Grade III Glioma
WHO Grade IV Glioma
Metastatic Brain Tumor
Diffuse Midline Glioma, H3 K27M-Mutant
Thalamus Tumor
Spinal Tumor
IDH1 Mutation
IDH1 R132
IDH1 R132C
IDH1 R132H
IDH1 R132S
IDH1 R132G
IDH1 R132L
Oligodendroglioma

Interventions

DRUG: Olutasidenib + TMZ

Sponsor

Rigel Pharmaceuticals

Collaborators

[object Object]